Study record
The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test
Yin X, Jing Y, Chen Q et al. · Eur J Pharmacol · 2020
AnimalMOTS-c administeredEvidence tier C
What this study reported
In the mouse formalin test, MOTS-c was associated with dose-dependently reduced phase-2 licking time, an effect attenuated by the AMPK antagonist compound C. MOTS-c also reduced serum pro-inflammatory cytokines, raised an anti-inflammatory cytokine, increased spinal AMPKα phosphorylation and suppressed formalin-induced ERK, JNK, p38 activation and c-fos expression.
Limitations
Males only in a single acute pain model; high-dose systemic exposure; group sizes not reported in the abstract.
Study record
| Study model | Animal study (in vivo) |
|---|---|
| Substance studied | MOTS-c administeredSynthetic MOTS-c was given to cells, animals or people. |
| Species | mouse |
| System studied | Male ICR mice in the formalin inflammatory nociception test |
| Population | Not reported |
| Design | Controlled animal experiment |
| Sample size as reported | Not reported |
| Control group | formalin-treated mice not given MOTS-c; AMPK antagonist compound C |
| Route (data field only) | intraperitoneal |
| Endpoints measured | paw-licking time; serum cytokines; spinal AMPKα phosphorylation; spinal ERK, JNK and p38 activation; spinal c-fos expression |
| Pathways measured | AMPK signalling · MAPK signalling · Inflammation |
| Research areas | Nervous system · Inflammation & immunity |
| Evidence tier | C — Animal in vivo |
| Publication types | Journal Article |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Mammalian
- Sample size
- Not reported
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Moderate
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.